Merck terminates influenza A/B collaboration with Cocrystal Pharma; effective March 14, 2024

Cocrystal Pharma, Inc.

Merck terminated Exclusive License and Research Collaboration Agreement for influenza A/B antiviral compounds, effective March 14, 2024.
Merck cited inability to develop compounds to meet specific program aspect; no existing conditions to continue collaboration.
Cocrystal received $4M upfront in 2019 and was eligible for milestone payments and royalties—now forfeited.
Pending patent applications on compounds covered by the Agreement remain in place.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cocrystal Pharma, Inc. terminated Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme LLC (effective 2023-12-15).

Action: termination
Agreement: license
Counterparty: Merck Sharp & Dohme LLC
Effective: 2023-12-15

Exact text from the filing

On December 15, 2023, Cocrystal Pharma, Inc. (the “Company”) received written notice from Merck Sharp & Dohme LLC (“Merck”) of Merck’s election to terminate the Exclusive License and Research Collaboration Agreement (the “Agreement”), dated January 2, 2019, by and between the Company and Merck, with respect to the collaboration with Merck on the development of influenza A/B antiviral compounds.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-045742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.